KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Working Capital Changes (2017 - 2025)

Alnylam Pharmaceuticals' Other Working Capital Changes history spans 17 years, with the latest figure at $170.7 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 166.28% year-over-year to $170.7 million; the TTM value through Dec 2025 reached $117.7 million, up 150.0%, while the annual FY2025 figure was $117.7 million, 150.0% up from the prior year.
  • Other Working Capital Changes reached $170.7 million in Q4 2025 per ALNY's latest filing, up from -$15.1 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $170.7 million in Q4 2025 to a low of -$257.5 million in Q4 2024.
  • Average Other Working Capital Changes over 5 years is -$6.6 million, with a median of -$11.7 million recorded in 2023.
  • Peak YoY movement for Other Working Capital Changes: skyrocketed 508.89% in 2022, then tumbled 889.02% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$66.0 million in 2021, then skyrocketed by 86.83% to -$8.7 million in 2022, then soared by 475.68% to $32.6 million in 2023, then crashed by 889.02% to -$257.5 million in 2024, then surged by 166.28% to $170.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Other Working Capital Changes are $170.7 million (Q4 2025), -$15.1 million (Q3 2025), and -$10.5 million (Q2 2025).